LLY

Eli Lilly & Co

Phase 3 Confirmed

Jaypirca

relapsed or refractory CLL or SLL

Resolved

68days ago

Phase 3 readout · Apr 30, 2026

What's at stake Phase 3 trial results for Jaypirca in relapsed or refractory CLL or SLL are due Apr 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 15h ago

“positive Phase 3 results from Jaypirca in combination with venetoclax and rituximab in relapsed or refractory CLL or SLL,”

Add to calendar Post on X Reddit

Provenance